Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

Successful Salvage with Inotuzumab Ozogamicin in Relapsed/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab

Alay Mansurov, MD, Michael Byrne, MD, Koyamangalath Krishnan, MD

Blood (2018) 132 (Supplement 1): 5452.

https://doi.org/10.1182/blood-2018-99-114170

Published: 2018

Journal Articles

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Amer M. Zeidan, MD, Rachel J. Cook, MD, Rodolfo Bordoni, MD, Ekaterine Asatiani, MD, Gongfu Zhou, Théa Faivre, Michael Byrne, MD, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 640.

https://doi.org/10.1182/blood.V130.Suppl_1.640.640

Published: 2017

Journal Articles

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Michael Byrne, MD, William Donnellan, Manish R Patel, MD, Amer M. Zeidan, MD, Mohamad Cherry, MDMS, Maria R. Baer, MD, Amir T. Fathi, MD MD BS, Jason Kaplan, MD, Feng Zhou, Fred Zheng, MD, April M. Barbour, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 2585.

https://doi.org/10.1182/blood.V130.Suppl_1.2585.2585

Published: 2017

Journal Articles

Similar Outcomes of Early Failure Steroid Dependent Acute GvHD and Upfront Steroid Refractory Acute GvHD: Implications on Clinical Trials

Karina A Mendoza, BS, Heidi Chen, PhD, Brian G Engelhardt, MD, Bipin N. Savani, MD, Stacey A Goodman, MD MS, Jeremy Warner, MD MS, Adetola A. Kassim, MD MS, Michael Byrne, MD, Wichai Chinratanalab, MD, John P. Greer, MD, Carole Hunt, Madan Jagasia, MD MBBS, MS

Blood (2017) 130 (Supplement 1): 1975.

https://doi.org/10.1182/blood.V130.Suppl_1.1975.1975

Published: 2017

Journal Articles

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Katie S Gatwood, PharmD, Kathryn A Culos, PharmD, Laura A Binari, MD, Brian G Engelhardt, MD, Adetola A. Kassim, MD MS, Michael Byrne, MD, Stacey A Goodman, MD MS, Wichai Chinratanalab, MD, Salyka M. Sengsayadeth, MD, John P. Greer, MD, Madan Jagasia, MD MBBS, MS, Bipin N. Savani, MD

Blood (2017) 130 (Supplement 1): 3210.

https://doi.org/10.1182/blood.V130.Suppl_1.3210.3210

Published: 2017

NARROW

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Successful Salvage with Inotuzumab Ozogamicin in Relapsed/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Similar Outcomes of Early Failure Steroid Dependent Acute GvHD and Upfront Steroid Refractory Acute GvHD: Implications on Clinical Trials

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Successful Salvage with Inotuzumab Ozogamicin in Relapsed/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab

A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies

Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies

Similar Outcomes of Early Failure Steroid Dependent Acute GvHD and Upfront Steroid Refractory Acute GvHD: Implications on Clinical Trials

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only